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Abstract
Objective: To report a case of delayed methotrexate (MTX) elimination while receiving concomitant
levetiracetam. Case Report: A 46-year-old man with relapsed osteosarcoma of the base of the skull
receiving high-dose MTX tolerated his first cycle of MTX with elimination to nontoxic MTX levels (≤0.1
µmol/L) within 90 hours. After hospital discharge, the patient experienced seizures secondary to brain
metastasis and started on levetiracetam, which was continued as maintenance therapy. The patient
experienced delayed MTX elimination during cycles 2, 3, and 4 while receiving levetiracetam. On
average, elimination to nontoxic MTX levels took 130 hours (106-144 hours). Before the fifth cycle of
MTX, lorazepam was substituted for the levetiracetam. MTX was eliminated to nontoxic levels within 95
hours. During all cycles, the patient received standard supportive care and serum creatinine remained
stable. No other drugs known to interact with MTX were administered. Discussion: This possible drug
interaction has only been reported once in the pediatric population. With a score of 6 on the Drug
Interaction Probability Scale for evaluating causation of drug interactions, it is probable that the delayed
MTX elimination was caused by an interaction with levetiracetam. Conclusion: Coadministration of
levetiracetam and MTX may result in delayed elimination of MTX, increasing the likelihood of toxicity.
Consideration should be given to temporarily switching from levetiracetam to another antiepileptic (ie,
lorazepam) to prevent this interaction. This is particularly important in those experiencing delayed
elimination with prior cycles of concomitant MTX and levetiracetam or those at greater risk for MTX
toxicity.

Introduction
Patients with cancer are at a high risk for drug-drug interactions because of the complex nature of
their treatment regimens. In fact, it has been reported that 12% to 63% of patients with cancer are
potentially exposed to interacting medications, and 75% of these interactions may be classified as
moderate or severe.1 Chemotherapeutic agents have complex pharmacological profiles, narrow
therapeutic indexes, and steep dose-toxicity curves.2 These drug properties leave little to no room
for alterations in the elimination or distribution of chemotherapeutic agents. Further complicating
the use of potentially toxic chemotherapy regimens is the complex nature of the oncology patient.
Many are on multiple maintenance medications to treat chronic conditions in addition to those
necessary to control the symptoms of their malignancy. Patients who develop central nervous
system metastases may experience seizure episodes and require long-term therapy with an
antiepileptic agent; however, optimal therapy with ongoing oncological treatment has not been
established.3 When choosing an antiepileptic medication, agents with a low potential for
interacting with chemotherapy and favorable safety profiles, such as levetiracetam, are preferred.3
Here, we present a case of delayed elimination when high-dose methotrexate (MTX) was
administered concomitantly with levetiracetam.
Case Report
A 46-year-old Caucasian male with relapsed osteosarcoma presented for chemotherapy with highdose MTX alternating with ifosfamide and etoposide according to the regimen utilized in the SFOP
OS94 protocol.4 He had a past medical history of retinoblastoma that was treated with radiation at
the age of 11 months, diabetes mellitus, hypertension, and hyperlipidemia. Home medications
included lisinopril, simvastatin, glipizide, and aspirin. He originally presented with headaches and
significant sinus complaints and was found to have radiation-induced osteosarcoma of the base of
the skull. This was treated with cisplatin and doxorubicin for 6 cycles followed by surgical
resection and adjuvant concurrent chemoradiation with carboplatin. The patient was disease free
for approximately 1 year, when he presented with epistaxis. On magnetic resonance imaging, he
was found to have a mass within the ethmoidal cells and the right orbit. On biopsy, this was
confirmed to be recurrent osteosarcoma.
During cycle 1 of chemotherapy for recurrent disease, the patient was admitted to the oncology
unit and received 24 g of MTX (12 g/m2) intravenously (IV) over 4 hours (height = 170 cm, weight
= 80 kg). Supportive care included leucovorin rescue with 25 mg orally every 6 hours and urinary
alkalinization with 100 mEq of sodium bicarbonate per liter of dextrose 5% in water at 125 mL/h
(3 L/d). Urine pH remained above 7, and recorded input and output were well balanced throughout
the hospital stay. Prior imaging in addition to history and physical exam on admission did not
reveal the presence of any findings suggestive of ascites or pleural effusion. Serum MTX levels
were drawn 24, 48, and 72 hours after the start of the MTX infusion, and every morning thereafter
until the level was <0.1 µmol/L. Baseline serum creatinine was 0.9 mg/dL, and aspartate and
alanine aminotransferases (AST/ALT) were within normal limits (10 and 39 U/L, respectively).
Additional medications administered to the patient during the admission were lisinopril,
simvastatin, insulin glargine, insulin aspart, oxycodone, prochlorperazine, ondansetron, and
famotidine. Aspirin was held until hospital discharge. The patient tolerated the first cycle of MTX
well and eliminated it to nontoxic levels (≤0.1 µmol/L) within 90 hours (Table 1). After hospital

discharge, the patient developed seizures as a result of large right-parietal/occipital lobe lesions
associated with edema and shifting toward the left hemisphere. Levetiracetam was initiated and
continued as maintenance therapy at 1 g orally every 12 hours, and 7 days after starting
levetiracetam, chemotherapy treatments were resumed.

During cycles 2, 3, and 4 of MTX, the patient experienced delayed elimination, with an average
time to nontoxic levels of 130 hours (106-155 hours; Figure 1). The patient continued to receive
the same dose of MTX as cycle 1 (12 g/m2) along with the same supportive care. Urine pH
remained above 7.0 from the start of each MTX infusion until levels were nontoxic, and recorded
input and output remained well balanced. History and physical exams during each admission did
not reveal the presence of any findings suggestive of ascites or pleural effusion. Changes to the
patient’s medications throughout cycles 2 to 4 included the addition of fluoxetine prior to cycle 3
and the discontinuation of lisinopril during cycle 4. No medications known to interact with MTX
were administered during the hospital stays for cycles 2 to 5 of MTX administration. During each
of these cycles, leucovorin was increased to 50-mg IV every 6 hours because of the elevated MTX
levels at 24 hours and continued until levels were nontoxic.
Prior to the fifth cycle of MTX, lorazepam was substituted for levetiracetam to control the patient’s
seizures. MTX was administered the same as in cycles 1 to 4 with the same supportive care. Urine
pH remained above 7, and recorded input and output were well balanced. Leucovorin was
increased to 50-mg IV every 6 hours because of the elevated MTX levels at 24 hours. Overall, the
patient eliminated MTX to nontoxic levels within 95 hours.

Discussion
It is well known that MTX interacts with multiple medications. Drugs that are highly protein
bound, including many antiepileptics, have been shown to reduce renal clearance of MTX through
protein-drug displacement and lead to increased serum concentrations, placing patients at risk for
toxicity.2 Additionally, active renal tubular secretion of MTX has been shown to be reduced by
drugs such as probenecid and weak organic acids.5 Delayed MTX elimination can lead to
significant toxicities, such as acute renal failure, bone marrow suppression, mucositis, and
hepatotoxicity. Levetiracetam displays less protein binding than other antiepileptics (<5%).6
Additionally, levetiracetam lacks any significant effects on the metabolism of medications via
hepatic enzymes (cytochrome P450, glucuronidation, etc) and is often a preferred agent because
of the decreased likelihood of adverse interactions and subsequent toxicities.7
A possible mechanism responsible for decreased MTX elimination when coadministered with
levetiracetam has not been proposed; however, it may be because of competition for tubular
secretion. Though levetiracetam undergoes glomerular filtration, the metabolite ucb L057 is
eliminated via active tubular secretion.8 When levetiracetam was coadministered with probenecid,
renal clearance of the metabolite ucb L057 was decreased by 60% and the Cmax doubled.8 MTX
also undergoes active tubular secretion and interacts with many medications that compete for
secretion. When administered with probenecid, MTX levels doubled.9 Given the similar
interactions with probenecid, it is plausible that with the common route of elimination, MTX and
levetiracetam’s metabolite ucb L057 may compete with each other for tubular secretion.
A search of the literature was performed using the search term methotrexate and levetiracetam
revealing 1 publication relating to a possible drug interaction. A pediatric case report was recently
published in which a 15-year-old boy with B-cell lymphoblastic leukemia was receiving treatment
with high-dose MTX.10 During treatment, he developed seizures, was diagnosed with brain
metastases, and initiated on oral levetiracetam. After the third infusion of high-dose MTX (5
g/m2/24 hour) the patient developed vomiting, renal failure, and hypertension. He was also found

to have an elevated serum creatinine and MTX level and required treatment with carboxypeptidase
G2. It was noted that the patient had no prior risk factors for MTX toxicity and was receiving no
concomitant interacting medications.
In the present case report, the patient did not experience any toxicity; however, MTX levels were
above the goal ranges at 24 (goal MTX level <10 µmol/L), 48 (goal MTX level <1 µmol/L), and
72 (goal MTX level <0.1 µmol/L) hours after the start of the MTX infusion when receiving
concomitant levetiracetam (Table 1). During cycle 5, the 24-hour MTX level was above goal
range; however, this may be because of the effect of residual levetiracetam present from
administration prior to hospital admission. Given a half-life of approximately 8 hours, it is
plausible that levetiracetam was still being eliminated and available to interact with MTX. This
was not the case for the 48-hour level, which was 0.69 µmol/L, well below the goal of 1 µmol/L.
Most important, the time to nontoxic MTX levels was shorter when levetiracetam was not
coadministered with the high-dose MTX (Table 1). During the fourth cycle of MTX, elimination
was not as delayed as during cycles 2 and 3. During all 3 of these cycles, the patient received the
same care, including the coadministration of levetiracetam; however, during cycle 4, the patient’s
lisinopril was held during the hospital stay. Though no interaction has been reported between
lisinopril and MTX, the renal vasoconstriction caused by this medication in the efferent arteriole
may decrease blood flow through the glomerulus, which theoretically could decrease MTX
elimination. Holding lisinopril may have slightly improved MTX clearance during cycle 4.
Lisinopril was administered during cycles 1 to 3 and during cycle 5.
Unfortunately, little data exist regarding the optimal treatment of seizures in cancer patients with
brain metastases. There are a multitude of drug interactions associated with many antiepileptic
medications, particularly via their hepatic enzyme–inducing effects and protein-binding effects.
For these reasons, agents such as phenytoin, phenobarbital, carbamazepine, oxcarbazepine, and
topiramate are not recommended as first-line agents.11 Valproate has been associated with
increased hematological toxicity when combined with chemotherapy and is best avoided if
possible.12 Benzodiazepines may be recommended in the acute treatment of seizures because of
their relative lack of drug interactions. For long-term treatment of seizures associated with brain
metastases, it has been recommended to utilize agents relatively free of drug interactions
(levetiracetam, gabapentin, lamotrigine, topiramate, and pregabalin).11
Until now, a potential drug interaction between MTX and levetiracetam has not been reported in
adults. The Drug Interaction Probability Scale (DIPS) was used to evaluate the causation of a
potential drug interaction between MTX and levetiracetam.13 With a DIPS score of 6, it is probable
that the delayed MTX elimination seen in this patient was the result of an interaction with
levetiracetam as evidenced by more rapid MTX elimination during cycles 1 and 5 with no
concomitant levetiracetam and delayed elimination during cycles 2, 3, and 4 with concomitant
levetiracetam (Table 2). Therefore, an interaction between MTX and levetiracetam cannot be ruled
out. Patients receiving concomitant levetiracetam and MTX who are experiencing delayed
elimination may benefit from the substitution of levetiracetam until MTX levels are nontoxic.
When possible, consideration should be given to temporarily switching from levetiracetam to
another antiepileptic (ie, lorazepam) to prevent this interaction. This is particularly important in

those who experienced delayed elimination with prior cycles of concomitant MTX and
levetiracetam coadministration or those felt to be at greater risk for MTX toxicity.
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